• NAYZILAM will be available in retail pharmacies on December 2, 2019
• Copay support and a patient assistance program will be provided by UCB for eligible NAYZILAM patients*

• The Phase 3 BE READY study, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints¹
• UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020

UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

UCB's Denelle Waynick, VP, Legal Affairs (U.S.), U.S. General Counsel and Global Head, Enterprise Risk Management, leads by example by being true to herself to encourage others to do so too. Read more from Denelle on why by being authentic to yourself, you become stronger as an individual, leader, and employee. Read the full article on LinkedIn.

UCB researchers like Jessica Williamson, PhD, come to work driven by a singular purpose – to create value for people living with severe disease. That’s because patients depend on the important work of scientific research to discover new medical innovations that will help them achieve their goals. Read more from Dr. Williamson about why she's passionate about innovating for patients and UCB's growing research presence in the greater Boston area.

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness. Check out the full infographic below.

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness.

• The Phase 3 BE VIVID study evaluating the efficacy and safety of bimekizumab in adults with moderate-to-severe chronic plaque psoriasis met all primary and ranked secondary endpointsⁱ

Learn more about living with non-radiographic axial spondyloarthritis (nr-axSpA) from Chelsea, who recently shared her story.

• Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab, an FcRn targeting antibody also in phase 3